Drugs / RSV 6120/ΔNS2/1030s
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03916185 | Jun 2019 → Jan 2024 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Mixed Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV 6120/ΔNS2/1030s | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03916185 ↗ |
| Modality | Vaccine | “the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines” NCT03916185 ↗ |
| Route | Intranasal | “administered as nose drops” NCT03916185 ↗ |